Telix Pharmaceuticals (Est) Pty. Ltd.
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, is a pioneering biopharmaceutical company focused on the development of innovative cancer therapies and diagnostic imaging solutions. Founded in 2015, Telix has rapidly established itself in the oncology sector, with a strong emphasis on radiopharmaceuticals that target specific cancer types. The company operates primarily in Australia, Europe, and North America, offering unique products such as TLX591 (a prostate cancer imaging agent) and TLX250 (for renal cancer). These therapies leverage advanced radiolabelled technology, setting Telix apart in a competitive market. With a commitment to improving patient outcomes, Telix Pharmaceuticals has achieved significant milestones, including successful clinical trials and strategic partnerships, solidifying its position as a leader in the field of targeted cancer treatment.
DitchCarbon Score
How does Telix Pharmaceuticals (Est) Pty. Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals (Est) Pty. Ltd.'s score of 16 is lower than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Telix Pharmaceuticals (Est) Pty. Ltd.'s reported carbon emissions
Telix Pharmaceuticals (Est) Pty. Ltd., headquartered in Australia, currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Telix Pharmaceuticals Limited, which may influence its climate commitments and reporting. As of now, there are no documented reduction targets or climate pledges from Telix Pharmaceuticals (Est) Pty. Ltd. This lack of specific initiatives suggests that the company may still be in the early stages of developing its climate strategy or reporting framework. Given the absence of direct emissions data and reduction initiatives, it is essential to consider the broader industry context. Many pharmaceutical companies are increasingly focusing on sustainability and carbon reduction, often setting science-based targets to align with global climate goals. Telix Pharmaceuticals (Est) Pty. Ltd. may benefit from adopting similar practices to enhance its environmental performance and transparency. In summary, while Telix Pharmaceuticals (Est) Pty. Ltd. does not currently report specific emissions data or reduction targets, its affiliation with Telix Pharmaceuticals Limited may provide a pathway for future climate commitments and initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Telix Pharmaceuticals (Est) Pty. Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
